局限期前列腺癌全盆腔与单纯前列腺调强弧治疗的肠道和泌尿生活质量比较
本研究纳入234例接受根治性VMAT(78 Gy/39次)的局限期前列腺癌患者,其中108例接受单纯前列腺VMAT,126例接受初始全盆腔VMAT(46.8 Gy/26次,同步整合推量)。采用EPIC前瞻性评估基线及治疗后3、6、12、24个月的生活质量,发现两组肠道和泌尿生活质量变化无显著组间差异,仅全盆腔组在12个月时对便血和总体肠道问题的个体条目报告更多中重度困扰,24个月时无差异。
要点
- 两组在24个月随访期内肠道和泌尿EPIC领域评分变化无显著差异。
- 全盆腔VMAT组12个月时便血和总体肠道问题个体条目报告更多中重度困扰。
- 24个月时所有个体条目均无显著组间差异。
核心结论
- 在24个月随访期内,单纯前列腺VMAT与全盆腔VMAT的肠道和泌尿生活质量总体相似,仅12个月时全盆腔组在特定肠道条目上报告更多中重度问题。
研究设计与样本
- 前瞻性研究,纳入234例接受根治性VMAT至78 Gy/39次的局限期前列腺癌患者,108例接受单纯前列腺VMAT,126例接受初始全盆腔VMAT至46.8 Gy/26次(同步整合推量)。
主要发现
- 基线生活质量评分两组无显著差异。
- 所有肠道和泌尿EPIC领域的生活质量自基线变化均无显著组间差异。
- 出现临床相关肠道和泌尿生活质量下降的患者比例在整个随访期两组相似。
- 12个月时全盆腔VMAT组报告便血(P = .039)和总体肠道问题(P = .008)中重度问题的可能性高于单纯前列腺VMAT组。
- 24个月时任何个体条目均无显著组间差异。
临床怎么用
- 对于局限期前列腺癌患者,全盆腔VMAT与单纯前列腺VMAT的肠道和泌尿生活质量总体相似,可作为选择放疗范围时的参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare bowel and urinary health-related quality of life (HRQOL) between prostate-only (PO) volumetric modulated arc therapy (VMAT) and whole-pelvis (WP) VMAT in patients with localized prostate cancer. METHODS AND MATERIALS: A total of 234 patients treated with definitive VMAT to 78 Gy in 39 fractions were enrolled. Of these, 108 patients received PO-VMAT and 126 patients received initial WP-VMAT to 46.8 Gy in 26 fractions using a simultaneous integrated boost technique. HRQOL was prospectively assessed before radiation therapy (baseline), and 3, 6, 12, and 24 months after treatment using the Expanded Prostate Cancer Index Composite (EPIC). RESULTS: Baseline HRQOL scores did not differ significantly between the 2 groups. No significant between-group differences in HRQOL change from baseline were observed for all bowel and urinary EPIC domains. The proportion of patients showing a clinically relevant decrease in bowel and urinary HRQOL scores from baseline was similar between the groups throughout the follow-up period. An analysis of individual HRQOL items showed that patients undergoing WP-VMAT were more likely to report moderate/big problems with bloody stools (P = .039) and overall bowel problems (P = .008) than those undergoing PO-VMAT at 12 months. There was no significant between-group difference in any individual items at 24 months, however. CONCLUSIONS: Bowel and urinary HRQOL is largely similar for patients receiving PO-VMAT and WP-VMAT during 24 months of follow-up, with the only differences seen in responses to specific bowel HRQOL items at 12 months.
引用
- Ishii K, Yamanaga T, Ogino R, et al. Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer. Pract Radiat Oncol. 2017. PMID: 29310978. doi:10.1016/j.prro.2017.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。